RxDoctor Payments Data

Deepak Talreja, MD

Interventional Cardiology · Virginia Beach, VANPI 1760451611

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,241,018 of the $1,493,148 with a category attached, or 83.1%. It is spread thinly across 45 manufacturers, the largest accounting for just 22.8%. Among interventional cardiology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,493,148in general payments, 2019–2025

Across 1,878 payments — averaging $795.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$341K
  • Lilly USA, LLC$242K
  • Novo Nordisk$107K
  • Boehringer Ingelheim$97K
  • AstraZeneca$82K
  • Bayer$76K
  • plus $548K from 39 others
$555,230in research payments, 2019–2025

Across 377 payments — averaging $1472.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$232K
  • Medtronic$111K
  • Boston Scientific$54K
  • Novo Nordisk AS$48K
  • Biotronik Inc.$46K
  • Cardiovascular Systems Inc.$33K
  • plus $32K from 3 others

What the payments were for

  • Consulting fees$104,1437%
  • Speaking & faculty fees$1,241,01883%
  • Travel & lodging$97,1177%
  • Food & beverage$49,2243%
  • Education$1370%
  • Other$1,5090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,493,148 in reported general payments places this provider in the 95th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$635,432
Medicare patients
2,273
Services billed
6,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$113,013
EntrestoSacubitril/Valsartan59$86,850
XareltoRivaroxaban57$71,751
JardianceEmpagliflozin45$66,190
FarxigaDapagliflozin Propanediol30$33,224
Repatha SureclickEvolocumab23$25,391
Repatha PushtronexEvolocumab29$20,644
Ranolazine ErRanolazine44$3,089
Rosuvastatin Calcium133$2,136
Metoprolol Succinate85$1,834
Ezetimibe59$955
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$892
Carvedilol108$868
Atorvastatin Calcium94$860
ClopidogrelClopidogrel Bisulfate86$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8,988$113,01394 claims
NovartisEntresto$17,445$86,85059 claims
Johnson & JohnsonXarelto$66,501$71,75157 claims
Boehringer IngelheimJardiance$97,050$66,19045 claims
AstraZenecaFarxiga$81,801$33,22430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →